Yersinia-specific antibodies in serum and synovial fluid in patients with Yersinia triggered reactive arthritis. 1994

O Mäki-Ikola, and R Lahesmaa, and J Heesemann, and R Merilahti-Palo, and R Saario, and A Toivanen, and K Granfors
National Public Health Institute, Department in Turku, Finland.

OBJECTIVE To further evaluate the role of bacterial antigens in triggering inflammation in the joint in patients with reactive arthritis by studying local antibody synthesis in the joint. METHODS Yersinia-specific antibodies in paired serum and synovial fluid samples from 29 patients with yersinia triggered reactive arthritis were studied using an enzyme linked immunosorbent assay (ELISA), an inhibition ELISA with six monoclonal antibodies against lipopolysaccharide or released proteins of yersinia and immunoblotting. Antibodies of IgM, IgG and IgA classes, as well as antibodies of IgA subclasses and those containing secretory component were measured against the lipopolysaccharide and the sodium dodecyl sulphate extract of whole Yersinia enterocolitica O:3 bacteria. RESULTS It was shown that yersinia-specific antibodies, as well as antibodies against other microbial antigens (rubella, measles, Bordetella pertussis, tetanus toxoid and Candida albicans) in synovial fluid mirror those in serum by concentration, by specificity and by distribution in classes and subclasses. CONCLUSIONS These results do not suggest any strong local antibody production, but indicate that the majority of yersinia antibodies in the synovial fluid are derived from the circulation.

UI MeSH Term Description Entries
D007070 Immunoglobulin A Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions. IgA,IgA Antibody,IgA1,IgA2,Antibody, IgA
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007075 Immunoglobulin M A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally was called a macroglobulin. Gamma Globulin, 19S,IgM,IgM Antibody,IgM1,IgM2,19S Gamma Globulin,Antibody, IgM
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

O Mäki-Ikola, and R Lahesmaa, and J Heesemann, and R Merilahti-Palo, and R Saario, and A Toivanen, and K Granfors
July 1987, Annals of the rheumatic diseases,
O Mäki-Ikola, and R Lahesmaa, and J Heesemann, and R Merilahti-Palo, and R Saario, and A Toivanen, and K Granfors
January 1992, British journal of rheumatology,
O Mäki-Ikola, and R Lahesmaa, and J Heesemann, and R Merilahti-Palo, and R Saario, and A Toivanen, and K Granfors
July 1986, Annals of the rheumatic diseases,
O Mäki-Ikola, and R Lahesmaa, and J Heesemann, and R Merilahti-Palo, and R Saario, and A Toivanen, and K Granfors
January 1989, The New England journal of medicine,
O Mäki-Ikola, and R Lahesmaa, and J Heesemann, and R Merilahti-Palo, and R Saario, and A Toivanen, and K Granfors
October 1987, Arthritis and rheumatism,
O Mäki-Ikola, and R Lahesmaa, and J Heesemann, and R Merilahti-Palo, and R Saario, and A Toivanen, and K Granfors
February 1991, Annals of the rheumatic diseases,
O Mäki-Ikola, and R Lahesmaa, and J Heesemann, and R Merilahti-Palo, and R Saario, and A Toivanen, and K Granfors
January 1988, Clinical and experimental rheumatology,
O Mäki-Ikola, and R Lahesmaa, and J Heesemann, and R Merilahti-Palo, and R Saario, and A Toivanen, and K Granfors
February 1991, Annals of the rheumatic diseases,
O Mäki-Ikola, and R Lahesmaa, and J Heesemann, and R Merilahti-Palo, and R Saario, and A Toivanen, and K Granfors
March 1989, Clinical and experimental immunology,
O Mäki-Ikola, and R Lahesmaa, and J Heesemann, and R Merilahti-Palo, and R Saario, and A Toivanen, and K Granfors
June 1989, The Journal of infectious diseases,
Copied contents to your clipboard!